研究者詳細 - 宇原　久

論文 - 宇原　久

分割表示 327 件中 121 - 140 件目／全件表示 >>

ダーモスコピーで診断困難であった脂漏性角化症の臨床的特徴

皆川茜, 古賀弘志, 高沢裕子, 宇原久, 奥山隆平

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 129 ( 4 ) 560 - 560 2019年04月

Decrease of Anti-DSG3, but Not Anti-DSG1 Antibody, After Cessation of Sitagliptin Treatment in a Patient With Pemphigus Vulgaris.

Toshiya Handa, Takafumi Kamiya, Yasuyuki Sumikawa, Tomoyuki Minowa, Ayako Kumagai, Masahide Sawada, Hisashi Uhara

JAMA dermatology 155 ( 3 ) 391 - 393 2019年03月 [国際誌]

DOI PubMed

抗PD-1抗体治療で著効し、治療中断後も再発のない悪性黒色腫の4例

半田稔也, 加藤潤史, 松井馨之, 箕輪智幸, 藤岡茉生, 澤田匡秀, 佐藤さゆり, 堀本浩平, 肥田時征, 澄川靖之, 宇原久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 129 ( 3 ) 353 - 353 2019年03月

結節性硬化症の皮膚病変に対するシロリムス外用療法の効果

肥田時征, 神谷崇文, 宇原久, 石川亜貴

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 129 ( 3 ) 356 - 356 2019年03月

アザチオプリンを投与中に汎発性帯状疱疹と汎血球減少を発症した1例

松井馨之, 澄川靖之, 箕輪智幸, 熊谷綾子, 神谷崇文, 宇原久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 129 ( 3 ) 356 - 356 2019年03月

A case of childhood-onset cutaneous mastocytosis with loss of wild-type KIT allele.

Hida T, Okura M, Kamiya T, Yamamoto M, Hori T, Uhara H

Journal of the European Academy of Dermatology and Venereology : JEADV 2019年02月 [査読有り]

DOI PubMed

リツキシマブが原因と考えられたTEN型薬疹の1例

松井馨之, 澄川靖之, 箕輪智幸, 熊谷綾子, 神谷崇文, 宇原久, 村瀬和幸

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 129 ( 1 ) 45 - 45 2019年01月

クローン型脂漏性角化症(clonal seborrheic keratosis)のダーモスコピー所見

半田稔也, 加藤潤史, 藤岡茉生, 堀本浩平, 肥田時征, 宇原久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 129 ( 1 ) 47 - 47 2019年01月

Dermoscopy of Melanoma and Non-melanoma Skin Cancers.

Junji Kato, Kohei Horimoto, Sayuri Sato, Tomoyuki Minowa, Hisashi Uhara

Frontiers in medicine 6 180 - 180 2019年 [国際誌]

Dermoscopy is a widely used non-invasive technique for diagnosing skin tumors. In melanocytic tumors, e.g., melanoma and basal cell carcinoma (BCC), the effectiveness of dermoscopic examination has been fully established over the past two decades. Moreover, dermoscopy has been used to diagnose non-melanocytic tumors. Here, we review novel findings from recent reports concerning dermoscopy of melanoma and non-melanoma skin cancers including BCC, sebaceous carcinoma, actinic keratosis, Bowen's disease, squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), extramammary Paget's disease (EMPD), and angiosarcoma.

DOI PubMed

【皮膚科で使うMTXの完全マニュアル】(Part4)乾癬以外の皮膚疾患へのMTXの応用(case (16)) リンパ腫様丘疹症

神谷崇文, 宇原久

Visual Dermatology ( (株)学研メディカル秀潤社 ) 18 ( 1 ) 96 - 97 2018年12月

Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.

Kenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, Hisashi Uhara, Hiroshi Uchi, Shusuke Yoshikawa, Sumiko Takatsuka, Hiroshi Koga, Naoko Wada, Hironobu Minami, Masahiro Hatsumichi, Suguru Asada, Yoshinobu Namba, Naoya Yamazaki

European journal of cancer (Oxford, England : 1990) 105 114 - 126 2018年12月 [査読有り] [国際誌]

AIM: The aim of the study was to evaluate the efficacy and safety of nivolumab combined with ipilimumab in treatment-naïve Japanese patients with advanced melanoma. METHODS: In this multicentre, single-arm study, treatment-naïve Japanese patients with unresectable stage III/IV or recurrent melanoma received nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for four doses, followed by biweekly doses of nivolumab (3 mg/kg). The primary end-point was centrally assessed objective response rate (ORR). Secondary end-points included overall survival (OS), progression-free survival (PFS), disease control rate and safety. RESULTS: The subtypes of the thirty patients enrolled were: 12, mucosal; eight, non-acral cutaneous; seven, acral; two, uveal and one, unknown primary melanoma. The ORR was 43.3% (95% confidence interval [CI]: 25.5, 62.6) with central and local assessment. The centrally and locally assessed disease control rate (95% CI) were 73.3% (54.1, 87.7) and 86.7% (69.3, 96.2), respectively. At the median follow-up period of 14.1 months (range 5.2-27.7), median OS and centrally assessed PFS were not reached. OS (95% CI) at 6, 12, 18 and 24 months was 93.3% (75.9, 98.3), 83.3% (64.5, 92.7), 72.9% (50.0, 86.5) and 65.6% (40.4, 82.2), respectively. Treatment-related adverse events (AEs) occurred in all patients. Grade III-IV and serious AEs occurred, mostly during the combination phase, in 23 (76.7%) and 20 (66.7%) patients, respectively. No treatment-related deaths occurred. CONCLUSIONS: This study confirmed the efficacy and safety of nivolumab plus ipilimumab in treatment-naïve Japanese patients with advanced melanoma including rare subtypes. Incidence rates for grade III-IV AEs were high but manageable with appropriate medical attention and treatment. TRIAL REGISTRATION: JapicCTI-152869.

DOI PubMed

血清CYFRA21-1値が病勢を反映した汗孔癌の1例

松井馨之, 加藤潤史, 藤岡茉生, 澤田匡秀, 佐藤さゆり, 堀本浩平, 肥田時征, 宇原久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 128 ( 12 ) 2666 - 2666 2018年11月

DPP-4阻害薬内服中に発症した尋常性天疱瘡の1例

半田稔也, 神谷崇文, 丸尾亜紀, 箕輪智幸, 大橋隆宏, 江畑加奈子, 熊谷綾子, 澄川靖之, 宇原久, 澤田匡秀, 兼古理恵

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 ) 128 ( 12 ) 2665 - 2665 2018年11月

Halo formations around senile hemangiomas in diffuse plane normolipemic xanthomatosis associated with monoclonal gammopathy.

Tokimasa Hida, Hiroki Takahashi, Kohichi Takada, Hisashi Uhara

JAAD case reports 4 ( 10 ) 1034 - 1036 2018年11月 [査読有り] [国際誌]

DOI PubMed

Transient hypogammaglobulinemia of infancy with no evidence of immunodeficiency other than atopic dermatitis: A case report and review of literature

Minowa T, Sumikawa Y, Hida T, Uhara H

J Cutan Immunol Allergy ( JOHN WILEY & SONS LTD ) 1 ( 5 ) 174 - 175 2018年11月 [査読有り]

DOI

Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy

T. Isei, K. Yokota, H. Uhara, Y. Fujisawa, T. Takenouchi, Y. Kiyohara, H. Uchi, H. Saruta, H. Ihn, T. Inozume, D. Watanabe, A. Takahashi, S. Fukushima, M. Tanaka, N. Yamazaki

Annals of oncology : official journal of the European Society for Medical Oncology 29 viii452 - viii453 2018年10月 [査読有り]

DOI PubMed

体温上昇により誘発された血管浮腫の2例

箕輪智幸, 澄川靖之, 半田稔也, 熊谷綾子, 神谷崇文, 宇原久

日本皮膚免疫アレルギー学会雑誌 ( (一社)日本皮膚免疫アレルギー学会 ) 2 ( 1 ) 164 - 164 2018年10月

痔核硬化剤に添加された亜硫酸塩の過敏症と考えられた1例

半田稔也, 箕輪智幸, 大橋隆宏, 江畑加奈子, 熊谷綾子, 神谷崇文, 澄川靖之, 宇原久

日本皮膚免疫アレルギー学会雑誌 ( (一社)日本皮膚免疫アレルギー学会 ) 2 ( 1 ) 184 - 184 2018年10月

小児毛孔性紅色粃糠疹にビタミンA製剤が奏効した1例

菅裕司, 澄川靖之, 宇原久

日本皮膚免疫アレルギー学会雑誌 ( (一社)日本皮膚免疫アレルギー学会 ) 2 ( 1 ) 181 - 181 2018年10月

Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.